{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2
  ],
  "modelUsed": "gemini-3-flash-preview",
  "metadata": {
    "studyName": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) I",
    "titles": [
      {
        "id": "title_1",
        "text": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",
        "type": {
          "code": "Official Study Title",
          "codeSystem": "USDM",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "NCT01776840",
        "scopeId": "org_ct_gov",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "NCT",
          "codeSystem": "USDM",
          "decode": "ClinicalTrials.gov Identifier"
        }
      },
      {
        "id": "sid_2",
        "text": "PCI-32765MCL3002",
        "scopeId": "org_1",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "SponsorProtocolNumber",
          "codeSystem": "USDM",
          "decode": "Sponsor Protocol Number"
        }
      },
      {
        "id": "sid_3",
        "text": "2012-004056-11",
        "scopeId": "org_eudract",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "EudraCT",
          "codeSystem": "USDM",
          "decode": "EudraCT Number"
        }
      },
      {
        "id": "sid_4",
        "text": "U1111-1137-0389",
        "scopeId": "org_unknown",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "WHO_UTN",
          "codeSystem": "USDM",
          "decode": "WHO Universal Trial Number"
        }
      },
      {
        "id": "sid_5",
        "text": "JNJ-54179060",
        "scopeId": "org_1",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "SponsorProtocolNumber",
          "codeSystem": "USDM",
          "decode": "Sponsor Protocol Number"
        }
      },
      {
        "id": "sid_6",
        "text": "EDMS-ERI-50002361",
        "scopeId": "org_1",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "SponsorProtocolNumber",
          "codeSystem": "USDM",
          "decode": "Sponsor Protocol Number"
        }
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "Janssen Research & Development, LLC",
        "type": {
          "id": "4cfd5b9e-b193-4cd0-b224-97f02c4e3baa",
          "code": "C54086",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Pharmaceutical Company",
          "instanceType": "Code"
        },
        "identifier": "Janssen Research & Development, LLC",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      },
      {
        "id": "org_2",
        "name": "US Food & Drug Administration",
        "type": {
          "id": "72aae9f7-ed95-4f15-ab57-752806936a1f",
          "code": "C25461",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Regulatory Agency",
          "instanceType": "Code"
        },
        "identifier": "US Food & Drug Administration",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      }
    ],
    "roles": [
      {
        "id": "role_1",
        "name": "Sponsor",
        "code": {
          "code": "Sponsor",
          "codeSystem": "USDM",
          "decode": "Sponsor"
        },
        "organizationIds": [
          "org_1"
        ],
        "instanceType": "StudyRole"
      },
      {
        "id": "role_2",
        "name": "Regulatory Authority",
        "code": {
          "code": "Regulatory Agency",
          "codeSystem": "USDM",
          "decode": "Regulatory Agency"
        },
        "organizationIds": [
          "org_2"
        ],
        "instanceType": "StudyRole"
      }
    ],
    "indications": [
      {
        "id": "ind_1",
        "name": "Newly Diagnosed Mantle Cell Lymphoma",
        "isRareDisease": false,
        "instanceType": "Indication",
        "description": "Mantle Cell Lymphoma"
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "USDM",
      "decode": "Phase3"
    },
    "studyType": "Interventional"
  },
  "rawResponse": {
    "titles": [
      {
        "id": "title_1",
        "text": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",
        "type": {
          "code": "OfficialStudyTitle",
          "codeSystem": "http://www.cdisc.org/USDM/titleType",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "NCT01776840",
        "identifierType": "NCT",
        "issuingOrganization": "ClinicalTrials.gov",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_2",
        "text": "PCI-32765MCL3002",
        "identifierType": "SponsorProtocolNumber",
        "issuingOrganization": "Janssen Research & Development",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_3",
        "text": "2012-004056-11",
        "identifierType": "EudraCT",
        "issuingOrganization": "EudraCT",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_4",
        "text": "U1111-1137-0389",
        "identifierType": "WHO_UTN",
        "issuingOrganization": "WHO",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_5",
        "text": "JNJ-54179060",
        "identifierType": "InternalStudyID",
        "issuingOrganization": "Sponsor",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_6",
        "text": "EDMS-ERI-50002361",
        "identifierType": "InternalStudyID",
        "issuingOrganization": "Sponsor",
        "instanceType": "StudyIdentifier"
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "Janssen Research & Development, LLC",
        "type": {
          "code": "Sponsor",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Sponsor"
        },
        "role": "Sponsor",
        "instanceType": "Organization"
      },
      {
        "id": "org_2",
        "name": "US Food & Drug Administration",
        "type": {
          "code": "RegulatoryAuthority",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Regulatory Authority"
        },
        "role": "Regulatory Authority",
        "instanceType": "Organization"
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "http://www.cdisc.org/USDM/studyPhase",
      "decode": "Phase 3"
    },
    "studyType": "Interventional",
    "indication": {
      "id": "ind_1",
      "name": "Newly Diagnosed Mantle Cell Lymphoma",
      "description": "Mantle Cell Lymphoma",
      "instanceType": "Indication"
    }
  }
}